NASDAQ:PRTO - Proteon Therapeutics Stock Price, Price Target & More

$2.45 +0.10 (+4.26 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$2.35
Today's Range$2.35 - $2.45
52-Week Range$1.10 - $2.85
Volume39,776 shs
Average Volume54,347 shs
Market Capitalization$43.30 million
P/E Ratio-1.14
Dividend YieldN/A
Beta1.51

About Proteon Therapeutics (NASDAQ:PRTO)

Proteon Therapeutics logoProteon Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on the development of pharmaceuticals to address the needs of patients with renal and vascular diseases. It develops vonapanitase, a recombinant human elastase, which is in Phase III clinical trial for patients with chronic kidney disease undergoing surgical creation of a radiocephalic fistula for hemodialysis; has completed a Phase I/II clinical trial in patients undergoing placement of an arteriovenous graft; and is in Phase I clinical trial for the treatment of symptomatic peripheral artery disease. The company was founded in 2001 and is based in Waltham, Massachusetts.

Receive PRTO News and Ratings via Email

Sign-up to receive the latest news and ratings for PRTO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:PRTO
CUSIPN/A
Phone781-890-0102

Debt

Debt-to-Equity RatioN/A
Current Ratio4.71%
Quick Ratio4.71%

Price-To-Earnings

Trailing P/E Ratio-1.14
Forward P/E Ratio-1.70
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.75 per share
Price / Book3.27

Profitability

EPS (Most Recent Fiscal Year)($2.13)
Net Income$-29,960,000.00
Net MarginsN/A
Return on Equity-128.00%
Return on Assets-73.90%

Miscellaneous

Employees16
Outstanding Shares17,670,000

How to Become a New Pot Stock Millionaire

Proteon Therapeutics (NASDAQ:PRTO) Frequently Asked Questions

What is Proteon Therapeutics' stock symbol?

Proteon Therapeutics trades on the NASDAQ under the ticker symbol "PRTO."

How were Proteon Therapeutics' earnings last quarter?

Proteon Therapeutics (NASDAQ:PRTO) posted its earnings results on Wednesday, March, 14th. The biopharmaceutical company reported ($0.31) EPS for the quarter, beating the Zacks' consensus estimate of ($0.45) by $0.14. View Proteon Therapeutics' Earnings History.

When is Proteon Therapeutics' next earnings date?

Proteon Therapeutics is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Proteon Therapeutics.

What price target have analysts set for PRTO?

5 brokerages have issued twelve-month target prices for Proteon Therapeutics' stock. Their predictions range from $2.00 to $6.00. On average, they anticipate Proteon Therapeutics' share price to reach $3.6667 in the next year. View Analyst Ratings for Proteon Therapeutics.

Who are some of Proteon Therapeutics' key competitors?

Who are Proteon Therapeutics' key executives?

Proteon Therapeutics' management team includes the folowing people:
  • Mr. Timothy P. Noyes, CEO, Pres & Director (Age 56)
  • Mr. George A. Eldridge, Sr. VP, CFO, Treasurer & Assistant Sec. (Age 55)
  • Dr. Steven Keith Burke M.D., Sr. VP & Chief Medical Officer (Age 57)
  • Mr. Matthew P. Kowalsky, VP of Legal & Sec. (Age 45)
  • Mr. Daniel P. Gottlieb, VP of Corp. Devel. (Age 48)

Has Proteon Therapeutics been receiving favorable news coverage?

Media stories about PRTO stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Proteon Therapeutics earned a coverage optimism score of 0.07 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 45.82 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Proteon Therapeutics?

Shares of PRTO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Proteon Therapeutics' stock price today?

One share of PRTO stock can currently be purchased for approximately $2.45.

How big of a company is Proteon Therapeutics?

Proteon Therapeutics has a market capitalization of $43.30 million. The biopharmaceutical company earns $-29,960,000.00 in net income (profit) each year or ($2.13) on an earnings per share basis. Proteon Therapeutics employs 16 workers across the globe.

How can I contact Proteon Therapeutics?

Proteon Therapeutics' mailing address is 200 WEST STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 781-890-0102 or via email at [email protected]


MarketBeat Community Rating for Proteon Therapeutics (PRTO)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  126 (Vote Outperform)
Underperform Votes:  122 (Vote Underperform)
Total Votes:  248
MarketBeat's community ratings are surveys of what our community members think about Proteon Therapeutics and other stocks. Vote "Outperform" if you believe PRTO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PRTO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Proteon Therapeutics (NASDAQ:PRTO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Proteon Therapeutics in the last 12 months. Their average twelve-month price target is $3.6667, suggesting that the stock has a possible upside of 49.66%. The high price target for PRTO is $6.00 and the low price target for PRTO is $2.00. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.402.402.202.11
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
8 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $3.6667$3.6667$3.4333$9.00
Price Target Upside: 49.66% upside70.54% upside85.59% upside592.31% upside

Proteon Therapeutics (NASDAQ:PRTO) Consensus Price Target History

Price Target History for Proteon Therapeutics (NASDAQ:PRTO)

Proteon Therapeutics (NASDAQ:PRTO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/16/2018HC WainwrightSet Price TargetHold$2.00HighView Rating Details
3/15/2018Robert W. BairdReiterated RatingOutperformHighView Rating Details
8/16/2017OppenheimerReiterated RatingMarket PerformLowView Rating Details
8/8/2017CowenReiterated RatingHoldLowView Rating Details
5/4/2017Maxim GroupSet Price TargetBuy$6.00HighView Rating Details
12/14/2016Raymond JamesReiterated RatingStrong-Buy -> Market PerformN/AView Rating Details
12/14/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
12/14/2016Stifel NicolausDowngradeBuy -> Hold$19.00 -> $3.00N/AView Rating Details
12/13/2016UBSDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Proteon Therapeutics (NASDAQ:PRTO) Earnings History and Estimates Chart

Earnings by Quarter for Proteon Therapeutics (NASDAQ:PRTO)

Proteon Therapeutics (NASDAQ:PRTO) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.44 EPS
Next Year EPS Consensus Estimate: $-1.24 EPS

Proteon Therapeutics (NASDAQ PRTO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018($0.37)N/AView Earnings Details
3/14/2018Q4 2017($0.45)($0.31)ViewN/AView Earnings Details
11/7/2017Q3 2017($0.40)($1.08)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.4370)($0.33)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.4260)($0.39)ViewN/AView Earnings Details
3/16/2017Q4 2016($0.43)($0.42)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.4620)($0.43)ViewN/AView Earnings Details
8/8/2016Q2 2016($0.42)($0.48)ViewN/AView Earnings Details
5/9/2016Q1($0.41)($0.40)ViewN/AView Earnings Details
3/14/2016($0.34)($0.39)ViewN/AView Earnings Details
11/12/2015Q315($0.33)($0.33)ViewN/AView Earnings Details
8/13/2015Q215($0.30)($0.31)ViewN/AView Earnings Details
5/13/2015($0.24)($0.28)ViewN/AView Earnings Details
3/20/2015($0.26)($0.24)ViewN/AView Earnings Details
11/25/2014($0.31)($31.03)$2.95 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Proteon Therapeutics (NASDAQ:PRTO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Proteon Therapeutics (NASDAQ PRTO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 36.30%
Institutional Ownership Percentage: 50.39%
Insider Trading History for Proteon Therapeutics (NASDAQ:PRTO)
Institutional Ownership by Quarter for Proteon Therapeutics (NASDAQ:PRTO)

Proteon Therapeutics (NASDAQ PRTO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/15/2017Steven Keith BurkeSVPBuy12,000$1.88$22,560.00117,535View SEC Filing  
11/30/2017James E FlynnDirectorBuy110,557$1.75$193,474.75View SEC Filing  
11/14/2017George Arthur EldridgeCFOBuy295$1.69$498.55View SEC Filing  
6/6/2016George Arthur EldridgeCFOBuy4,000$5.78$23,120.002,750View SEC Filing  
12/1/2015Timothy P. NoyesCEOSell5,000$14.97$74,850.00View SEC Filing  
11/2/2015Timothy P. NoyesCEOSell5,000$13.50$67,500.00View SEC Filing  
10/1/2015Timothy P. NoyesCEOSell5,000$13.33$66,650.00View SEC Filing  
9/8/2015Timothy P. NoyesCEOSell5,000$13.55$67,750.00View SEC Filing  
7/7/2015Daniel Philip GottliebVPSell1,965$16.86$33,129.90View SEC Filing  
10/27/2014James E FlynnInsiderBuy691,713$10.00$6,917,130.00View SEC Filing  
10/27/2014Skyline Venture Partners QualiMajor ShareholderSell56,038$10.00$560,380.00View SEC Filing  
10/27/2014Timothy HainesDirectorBuy950,000$10.00$9,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Proteon Therapeutics (NASDAQ PRTO) News Headlines

Source:
DateHeadline
Proteon Therapeutics (PRTO) Given Consensus Recommendation of "Hold" by AnalystsProteon Therapeutics (PRTO) Given Consensus Recommendation of "Hold" by Analysts
www.americanbankingnews.com - April 18 at 7:24 PM
Proteon Therapeutics (PRTO) Stock Rating Lowered by Zacks Investment ResearchProteon Therapeutics (PRTO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 18 at 5:18 PM
Proteon Therapeutics (PRTO) Given a $2.00 Price Target by HC Wainwright AnalystsProteon Therapeutics (PRTO) Given a $2.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - April 11 at 11:52 PM
 Analysts Anticipate Proteon Therapeutics (PRTO) to Post -$0.35 Earnings Per Share Analysts Anticipate Proteon Therapeutics (PRTO) to Post -$0.35 Earnings Per Share
www.americanbankingnews.com - April 10 at 11:16 PM
Proteon Therapeutics (PRTO) Upgraded at Zacks Investment ResearchProteon Therapeutics (PRTO) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 7 at 12:03 AM
Proteon Therapeutics (PRTO) Given Hold Rating at HC WainwrightProteon Therapeutics (PRTO) Given Hold Rating at HC Wainwright
www.americanbankingnews.com - April 1 at 10:29 AM
Proteon Therapeutics (PRTO) Downgraded by Zacks Investment ResearchProteon Therapeutics (PRTO) Downgraded by Zacks Investment Research
www.americanbankingnews.com - March 28 at 9:48 PM
Zacks: Analysts Anticipate Proteon Therapeutics Inc (PRTO) to Post -$0.35 Earnings Per ShareZacks: Analysts Anticipate Proteon Therapeutics Inc (PRTO) to Post -$0.35 Earnings Per Share
www.americanbankingnews.com - March 25 at 1:26 AM
Proteon Therapeutics Inc (PRTO) Given Average Recommendation of "Hold" by BrokeragesProteon Therapeutics Inc (PRTO) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - March 24 at 7:33 PM
Proteon Therapeutics (PRTO) Upgraded to "Hold" by Zacks Investment ResearchProteon Therapeutics (PRTO) Upgraded to "Hold" by Zacks Investment Research
www.americanbankingnews.com - March 18 at 11:14 AM
Proteon Therapeutics (PRTO) Given a $3.00 Price Target by Robert W. Baird AnalystsProteon Therapeutics (PRTO) Given a $3.00 Price Target by Robert W. Baird Analysts
www.americanbankingnews.com - March 17 at 2:18 PM
Proteon Therapeutics (PRTO) PT Set at $2.00 by HC WainwrightProteon Therapeutics (PRTO) PT Set at $2.00 by HC Wainwright
www.americanbankingnews.com - March 16 at 7:47 PM
Robert W. Baird Reaffirms Outperform Rating for Proteon Therapeutics (PRTO)Robert W. Baird Reaffirms Outperform Rating for Proteon Therapeutics (PRTO)
www.americanbankingnews.com - March 16 at 7:12 PM
Proteon Therapeutics (PRTO) Posts  Earnings Results, Beats Estimates By $0.14 EPSProteon Therapeutics (PRTO) Posts Earnings Results, Beats Estimates By $0.14 EPS
www.americanbankingnews.com - March 15 at 1:56 PM
Proteon Therapeutics Inc (NASDAQ:PRTO): Are Analysts Optimistic?Proteon Therapeutics Inc (NASDAQ:PRTO): Are Analysts Optimistic?
finance.yahoo.com - March 14 at 10:10 AM
Proteon Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial ResultsProteon Therapeutics Announces Fourth Quarter and Full-Year 2017 Financial Results
finance.yahoo.com - March 14 at 10:10 AM
 Analysts Anticipate Proteon Therapeutics Inc (PRTO) to Post -$0.43 EPS Analysts Anticipate Proteon Therapeutics Inc (PRTO) to Post -$0.43 EPS
www.americanbankingnews.com - March 7 at 5:11 PM
Proteon Therapeutics (PRTO) Set to Announce Earnings on WednesdayProteon Therapeutics (PRTO) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - March 7 at 1:50 AM
Proteon Therapeutics Completes Enrollment in PATENCY-2, Phase 3 Clinical Trial of Investigational VonapanitaseProteon Therapeutics Completes Enrollment in PATENCY-2, Phase 3 Clinical Trial of Investigational Vonapanitase
finance.yahoo.com - March 5 at 5:10 PM
Analyzing Proteon Therapeutics (PRTO) & Sorrento Therapeutics (SRNE)Analyzing Proteon Therapeutics (PRTO) & Sorrento Therapeutics (SRNE)
www.americanbankingnews.com - February 6 at 1:14 AM
Proteon Therapeutics Inc (PRTO) Given Consensus Recommendation of "Hold" by BrokeragesProteon Therapeutics Inc (PRTO) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - February 2 at 7:42 PM
 Analysts Anticipate Proteon Therapeutics Inc (PRTO) Will Announce Earnings of -$0.43 Per Share Analysts Anticipate Proteon Therapeutics Inc (PRTO) Will Announce Earnings of -$0.43 Per Share
www.americanbankingnews.com - February 2 at 1:16 AM
Proteon Therapeutics (PRTO) Lifted to Hold at Zacks Investment ResearchProteon Therapeutics (PRTO) Lifted to Hold at Zacks Investment Research
www.americanbankingnews.com - January 7 at 11:52 PM
Zacks: Analysts Anticipate Proteon Therapeutics Inc (PRTO) Will Post Earnings of -$0.43 Per ShareZacks: Analysts Anticipate Proteon Therapeutics Inc (PRTO) Will Post Earnings of -$0.43 Per Share
www.americanbankingnews.com - December 30 at 7:46 AM
Reviewing Aduro BioTech (ADRO) and Proteon Therapeutics (PRTO)Reviewing Aduro BioTech (ADRO) and Proteon Therapeutics (PRTO)
www.americanbankingnews.com - December 25 at 11:42 PM
Proteon Therapeutics Inc (PRTO) SVP Steven Keith Burke Purchases 12,000 SharesProteon Therapeutics Inc (PRTO) SVP Steven Keith Burke Purchases 12,000 Shares
www.americanbankingnews.com - December 18 at 6:52 PM
Proteon Therapeutics Inc (PRTO) Given Consensus Rating of "Hold" by BrokeragesProteon Therapeutics Inc (PRTO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - December 14 at 9:28 PM
Reviewing Proteon Therapeutics (PRTO) and The CompetitionReviewing Proteon Therapeutics (PRTO) and The Competition
www.americanbankingnews.com - December 14 at 1:28 PM
-$0.43 EPS Expected for Proteon Therapeutics Inc (PRTO) This Quarter-$0.43 EPS Expected for Proteon Therapeutics Inc (PRTO) This Quarter
www.americanbankingnews.com - December 13 at 3:24 AM
Proteon Therapeutics (PRTO) & Its Peers Financial ContrastProteon Therapeutics (PRTO) & Its Peers Financial Contrast
www.americanbankingnews.com - December 9 at 3:14 AM
Proteon Therapeutics (PRTO) and Its Peers Head-To-Head ReviewProteon Therapeutics (PRTO) and Its Peers Head-To-Head Review
www.americanbankingnews.com - December 9 at 3:14 AM
Proteon Therapeutics Inc (PRTO) Director Acquires $193,474.75 in StockProteon Therapeutics Inc (PRTO) Director Acquires $193,474.75 in Stock
www.americanbankingnews.com - December 4 at 6:36 PM
Critical Contrast: Proteon Therapeutics (PRTO) versus Its PeersCritical Contrast: Proteon Therapeutics (PRTO) versus Its Peers
www.americanbankingnews.com - December 4 at 1:30 PM
-$0.41 Earnings Per Share Expected for Proteon Therapeutics, Inc. (PRTO) This Quarter-$0.41 Earnings Per Share Expected for Proteon Therapeutics, Inc. (PRTO) This Quarter
www.americanbankingnews.com - November 25 at 9:26 AM
Proteon Therapeutics, Inc. (PRTO) Given Average Recommendation of "Hold" by AnalystsProteon Therapeutics, Inc. (PRTO) Given Average Recommendation of "Hold" by Analysts
www.americanbankingnews.com - November 19 at 5:34 PM
Analyzing Proteon Therapeutics (PRTO) & The CompetitionAnalyzing Proteon Therapeutics (PRTO) & The Competition
www.americanbankingnews.com - November 16 at 3:36 PM
Proteon Therapeutics, Inc. (PRTO) Earns "Hold" Rating from Robert W. BairdProteon Therapeutics, Inc. (PRTO) Earns "Hold" Rating from Robert W. Baird
www.americanbankingnews.com - November 11 at 11:12 AM
Proteon Therapeutics, Inc. (PRTO) Rating Lowered to Strong Sell at Zacks Investment ResearchProteon Therapeutics, Inc. (PRTO) Rating Lowered to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - November 11 at 7:16 AM
Proteon Therapeutics to Present at the Stifel 2017 Healthcare Conference November 15thProteon Therapeutics to Present at the Stifel 2017 Healthcare Conference November 15th
finance.yahoo.com - November 9 at 11:56 AM
Proteon Therapeutics Announces Third Quarter 2017 Financial ResultsProteon Therapeutics Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 9:03 AM
Proteon Therapeutics reports 3Q lossProteon Therapeutics reports 3Q loss
finance.yahoo.com - November 7 at 9:03 AM
-$0.40 EPS Expected for Proteon Therapeutics, Inc. (PRTO) This Quarter-$0.40 EPS Expected for Proteon Therapeutics, Inc. (PRTO) This Quarter
www.americanbankingnews.com - November 6 at 9:59 AM
Critical Comparison: Biopharmx Corp (BPMX) vs. Proteon Therapeutics (PRTO)Critical Comparison: Biopharmx Corp (BPMX) vs. Proteon Therapeutics (PRTO)
www.americanbankingnews.com - November 4 at 9:28 PM
Critical Review: Intec Pharma (NTEC) vs. Proteon Therapeutics (PRTO)Critical Review: Intec Pharma (NTEC) vs. Proteon Therapeutics (PRTO)
www.americanbankingnews.com - November 1 at 2:20 PM
Proteon Therapeutics, Inc. (PRTO) Set to Announce Quarterly Earnings on MondayProteon Therapeutics, Inc. (PRTO) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 30 at 9:54 AM
Proteon Therapeutics, Inc. (PRTO) Given Average Recommendation of "Hold" by BrokeragesProteon Therapeutics, Inc. (PRTO) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - October 25 at 9:52 PM
Zacks Investment Research Downgrades Proteon Therapeutics, Inc. (PRTO) to HoldZacks Investment Research Downgrades Proteon Therapeutics, Inc. (PRTO) to Hold
www.americanbankingnews.com - October 18 at 6:08 AM
Zacks: Brokerages Anticipate Proteon Therapeutics, Inc. (PRTO) to Post -$0.40 EPSZacks: Brokerages Anticipate Proteon Therapeutics, Inc. (PRTO) to Post -$0.40 EPS
www.americanbankingnews.com - October 17 at 6:22 PM
Proteon Therapeutics, Inc. (PRTO) Given Consensus Rating of "Hold" by BrokeragesProteon Therapeutics, Inc. (PRTO) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - September 30 at 8:34 PM
Head-To-Head Contrast: NeuroDerm (NDRM) & Proteon Therapeutics (PRTO)Head-To-Head Contrast: NeuroDerm (NDRM) & Proteon Therapeutics (PRTO)
www.americanbankingnews.com - September 22 at 6:06 AM

SEC Filings

Proteon Therapeutics (NASDAQ:PRTO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Proteon Therapeutics (NASDAQ:PRTO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Proteon Therapeutics (NASDAQ PRTO) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.